Lupin US FDA Inspection Concludes with 3 Observations

Lupin discloses US FDA inspection at Somerset, New Jersey facility from April 13-17, 2026.
Inspection closed with Form-483 containing three observations requiring company response.
Company commits to address observations and respond to FDA within stipulated timeframe.
Disclosure made pursuant to SEBI Listing Regulations Regulation 30 requirements.